Ipsen S.A. Non-GAAP EPS of Euro12.09, revenue of Euro3.68B; sets full-year 2026 guidance and mid-term outlook
Source: SeekingAlpha
2026-02-12 01:25:38 ET
More on Ipsen S.A.
- Ipsen S.A. (IPSEY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
- Seeking Alpha’s Quant Rating on Ipsen S.A.
- Historical earnings data for Ipsen S.A.
- Dividend scorecard for Ipsen S.A.
Read the full article on Seeking Alpha
For further details see:
Ipsen S.A. Non-GAAP EPS of €12.09, revenue of €3.68B; sets full-year 2026 guidance and mid-term outlook
Ipsen ADR
NASDAQ: IPSEY
IPSEY Trading
0.0% G/L:
$46.31 Last:
4,394 Volume:
$46.31 Open:
IPSEY Latest News
December 07, 2025 05:33:00 pm
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025
December 05, 2025 05:00:00 am
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting
June 02, 2025 08:00:00 am
PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer
